Investigating the relationship between sleep disturbances and cortical thickness, brainstem volume, amyloid accumulation, and inflammatory markers in Parkinson's disease patients.

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundThis study aimed to explore the relationship between self-reported sleep disturbances (e.g., insomnia, REM sleep behavior disorder [RBD]) and cortical thickness, brainstem volume, amyloid accumulation, and inflammatory markers in Parkinson's disease (PD) patients.MethodsWe conducted a cross-sectional study comparing 100 PD patients (observation group) with 100 age-matched controls. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), and serum levels of amyloid-beta (Aβ1-42), α-synuclein, and inflammatory markers (CRP, TNF-α, IL-1β) were quantified.ResultsPD patients exhibited significantly poorer sleep quality (PSQI total score: 2.11 ± 0.27 vs. 0.52 ± 0.02, P 3 vs. 3185.16 ± 255.41 mm3, P = 0.007) compared to controls. Biomarker profiling revealed elevated amyloid pathology in PD, with higher serum Aβ1-42 (median [IQR]: 1.98 [1.75-2.22] vs. 1.14 [1.10-1.19], P ConclusionThese findings highlight the interplay between neuroanatomical changes, amyloid pathology, and systemic inflammation in PD-related sleep dysfunction, suggesting potential therapeutic targets.

Related topics